BP000020-CYT-281: Recombinant Human Fibroblast Growth Factor 21 (FGF 21) Protein, His Tag
Source: E. coli-derived.
Measured in a cell proliferation assay using NIH-3T3 cells. The ED50 for this effect is < 12 ug/ml, which corresponds to > 83,000 units/ml.
Purity: > 90.0% by SDS-PAGE.BP000020-CYT-339: Recombinant Mouse Fibroblast Growth Factor 21 (FGF 21) Protein
Source: E. coli-derived.
Purity: > 95.0% by SDS-PAGE.BP000020-CYT-474: Recombinant Human Fibroblast Growth Factor 21 (FGF 21) Protein
Source: E. coli-derived.
Purity: > 95.0% by RP-HPLC and SDS-PAGE.
BP000020-CYT-130: Recombinant Rat Fibroblast Growth Factor 21 (FGF-21) Protein
Source: E. coli-derived.
Fully biologically active when compared to standard. The ED50 determined by a cell proliferation assay using murine NIH/3T3 cells is less than 700 ng/ml, corresponding to a specific activity of > 1.4 ?1000 IU/mg in the presence of 5 ug/ml of rMuKlotho-beta.
Purity: > 95.0% as determined by Gel Filtratio and SDS-PAGE.BP000020-CYT-516: Recombinant Mouse Fibroblast Growth Factor 21 (FGF 21) Protein, His Tag
Source: E. coli-derived.
Purity: > 95.0% by RP-HPLC and SDS-PAGE.BP000185-CYT-428: Recombinant Human FGF 22
Source: E. coli-derived.
Purity > 97%, by SDS-PAGE and RP-HPLC.BP000186-CYT-020: Recombinant Human FGF 23
Source: E. coli-derived.
The biological activity was measured in a cell proliferation assay using NIH/3T3 mouse embryonic fibroblasts. The ED50 for this effect is typically 0.05-0.5 ug/ml in the presence of 5 ug/ml of Recombinant Mouse Klotho and 10 ug/ml of heparin.
Purity > 95%, by SDS-PAGE.BP000186-CYT-028: Recombinant Human FGF 23 C-Terminal
Source: E. coli-derived.
Purity: > 90.0% as determined by densitometric image analysis.
Applications: WB.BP000186-CYT-374: Recombinant Human FGF 23, His Tag
Source: E. coli-derived.
Treatment with hrFGF23 has been shown to induce FGFR mediated Erk phosphorylation, reduce plasma PTH levels in rats and to reduce blood phosphate levels (Ref 1).
Purity > 90%, by SDS-PAGE and RP-HPLC.